Syros Pharmaceuticals, Inc.

OTCPK:SYRS Stock Report

Market Cap: US$946.1k

Syros Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:SYRS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Dec 24SellUS$2,333Srinivas AkkarajuIndividual9,333US$0.25
02 Dec 24SellUS$10,016Nancy SimonianIndividual37,070US$0.27
25 Nov 24SellUS$35,739Nancy SimonianIndividual134,713US$0.27
20 Nov 24SellUS$412,849Samsara BioCapital LLCCompany1,786,427US$0.26
19 Nov 24SellUS$10,321Gerald QuirkIndividual46,657US$0.22
18 Nov 24SellUS$28,980Jason HaasIndividual137,803US$0.21
18 Nov 24SellUS$2,382David RothIndividual12,099US$0.20
18 Nov 24SellUS$7,949Kristin StephensIndividual36,133US$0.22
18 Nov 24SellUS$26,932Conley CheeIndividual134,797US$0.20
12 Sep 24BuyUS$161,240Jason HaasIndividual100,000US$1.68
11 Sep 24BuyUS$160,680Conley CheeIndividual100,000US$1.71

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SYRS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders155,6740.58%
Institutions945,8303.52%
General Public25,730,95395.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 4.11% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
1.98%
Adage Capital Management, L.P.
531,914US$18.8k0%no data
0.93%
Acadian Asset Management LLC
249,426US$8.8k0%no data
0.31%
Baader Bank AG, Asset Management Arm
83,864US$3.0k280%no data
0.15%
1492 Capital Management, LLC
39,244US$1.4k0%no data
0.12%
Timothy Tyson
33,189US$1.2k0%no data
0.1%
Eric Olson
28,152US$992.70%no data
0.06%
FNY Investment Advisers, LLC
16,100US$567.7216%no data
0.06%
Peter Karl Wirth
16,000US$564.20%no data
0.06%
Marsha Fanucci
16,000US$564.20%no data
0.06%
Andrew Oh
16,000US$564.20%no data
0.06%
Sue Eckhardt
16,000US$564.20%no data
0.045%
Deborah Dunsire
12,000US$423.10%no data
0.04%
Richard Young
10,667US$376.10%no data
0.037%
XTX Holdings Limited, Asset Management Arm
10,053US$354.5-87.7%no data
0.018%
Lord, Abbett & Co. LLC
4,840US$170.70%no data
0.015%
Simplex Trading, LLC, Asset Management Arm
4,123US$145.40%no data
0.015%
Nancy Simonian
4,000US$141.10%no data
0.014%
Mark J. Alles
3,666US$129.20%no data
0.0075%
Dimensional Fund Advisors LP
2,000US$70.50%no data
0.0075%
Pharus Management Lux SA
2,000US$70.50%no data
0.0043%
Bg Fund Management Luxembourg S.A.
1,160US$40.90%no data
0.0019%
Blackstone Alternative Investment Advisors LLC
500US$17.60%no data
0.0019%
Point72 Asset Management, L.P.
496US$17.50%no data
0.00025%
L2 Asset Management, LLC
68US$2.40%no data
0.00013%
Guggenheim Partners, LLC
34US$1.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 20:08
End of Day Share Price 2025/05/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syros Pharmaceuticals, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark BreidenbachOppenheimer & Co. Inc.
Zegbeh JallahRoth Capital Partners
Philip NadeauTD Cowen